Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04946656 · ClinicalTrials.gov registry record · NA
A Study of SPG Block for Opioid Withdrawal
A NA study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT04946656 is a NA study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 3 participants.
The verdict
NCT04946656, a NA study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
Medication is the most efficacious treatment of an opioid use disorder, including methadone, buprenorphine, and naltrexone. However, many patients experience withdrawal symptoms, which prevents them from being successfully inducted onto medication for opioid use disorder. This study is a pilot study investigating whether blocking the SPG helps reduce withdrawal symptoms in OUD. This study does not involve treatment or induction onto medications. It is a proof of principal study only. We will recruit non-treatment seeking subjects with OUD who are admitted to the research unit for all procedures.
Interventions
- PROCEDURE sphenopalatine ganglion block
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2023-02-03 |
| Est. Completion | 2025-09-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04946656
The ClinicalTrials.gov registry entry for NCT04946656 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sphenopalatine ganglion block is the first listed.
NCT04946656 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04946656 about?
NCT04946656 is a clinical study titled "A Study of SPG Block for Opioid Withdrawal". Medication is the most efficacious treatment of an opioid use disorder, including methadone, buprenorphine, and naltrexone. However, many patients experience withdrawal symptoms, which prevents them from being successfully inducted onto medication for opioid use disorder. This study is a pilot study...
What is the current status of trial NCT04946656?
This trial is currently completed. It is a NA study. The enrollment target is 3 participants. The study started on 2023-02-03. Estimated completion is 2025-09-03.
What interventions are being tested in trial NCT04946656?
The interventions under investigation include: sphenopalatine ganglion block (PROCEDURE).
Who is sponsoring clinical trial NCT04946656?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.